IA
IMNP

IFP Advisors’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

IFP Advisors’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1
Closed – – 4312
2017
Q3 		$0 Hold
1
– – ﹤0.01% 4331
2017
Q2 		$0 Buy
+1
New +$3 ﹤0.01% 4331
2017
Q1 		– Hold
0
– – – 4254

Other funds holding IMNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

IFP Advisors's IMNP Position: Q4 2017 in Review

IFP Advisors sold out of Immune Pharmaceuticals Inc. (IMNP) in Q4 2017, closing a stake of 1 share.

IFP Advisors first reported a position in IMNP in Q2 2017 and held it in 2 quarters. The position peaked at $0 in Q3 2017. 15 funds tracked by Wall St. Rank hold IMNP as of Q4 2017.

  • IFP Advisors reported no remaining Immune Pharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
  • IFP Advisors sold 1 Immune Pharmaceuticals Inc. share in Q4 2017.
  • IFP Advisors first reported a position in Immune Pharmaceuticals Inc. in Q2 2017 and held it in 2 quarters.
  • IFP Advisors's Immune Pharmaceuticals Inc. position peaked at $0 in Q3 2017.
  • 15 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q4 2017.

Based on IFP Advisors's 13F filing for Q4 2017, filed 24 Jan 2018.